BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 24857234)

  • 1. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors.
    Edmonds EC; Delano-Wood L; Clark LR; Jak AJ; Nation DA; McDonald CR; Libon DJ; Au R; Galasko D; Salmon DP; Bondi MW;
    Alzheimers Dement; 2015 Apr; 11(4):415-24. PubMed ID: 24857234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistically Derived Subtypes and Associations with Cerebrospinal Fluid and Genetic Biomarkers in Mild Cognitive Impairment: A Latent Profile Analysis.
    Eppig JS; Edmonds EC; Campbell L; Sanderson-Cimino M; Delano-Wood L; Bondi MW;
    J Int Neuropsychol Soc; 2017 Aug; 23(7):564-576. PubMed ID: 28578726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates.
    Bondi MW; Edmonds EC; Jak AJ; Clark LR; Delano-Wood L; McDonald CR; Nation DA; Libon DJ; Au R; Galasko D; Salmon DP
    J Alzheimers Dis; 2014; 42(1):275-89. PubMed ID: 24844687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype.
    Bangen KJ; Clark AL; Werhane M; Edmonds EC; Nation DA; Evangelista N; Libon DJ; Bondi MW; Delano-Wood L;
    J Alzheimers Dis; 2016 Mar; 52(3):849-61. PubMed ID: 27031472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2014 Sep; 20(8):836-47. PubMed ID: 25156329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
    Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
    Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Missed" Mild Cognitive Impairment: High False-Negative Error Rate Based on Conventional Diagnostic Criteria.
    Edmonds EC; Delano-Wood L; Jak AJ; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2016 Mar; 52(2):685-91. PubMed ID: 27031477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing neuropsychological, typical, and ADNI criteria for the diagnosis of mild cognitive impairment in Vietnam-era veterans.
    Ly MT; Adler J; Ton Loy AF; Edmonds EC; Bondi MW; Delano-Wood L;
    J Int Neuropsychol Soc; 2024 Jun; 30(5):439-447. PubMed ID: 38263745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous cortical atrophy patterns in MCI not captured by conventional diagnostic criteria.
    Edmonds EC; Eppig J; Bondi MW; Leyden KM; Goodwin B; Delano-Wood L; McDonald CR;
    Neurology; 2016 Nov; 87(20):2108-2116. PubMed ID: 27760874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
    Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
    Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease.
    Sun X; Dong C; Levin B; Crocco E; Loewenstein D; Zetterberg H; Blennow K; Wright CB;
    Alzheimers Dement; 2016 Nov; 12(11):1159-1166. PubMed ID: 27321472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Wolfsgruber S; Polcher A; Koppara A; Kleineidam L; Frölich L; Peters O; Hüll M; Rüther E; Wiltfang J; Maier W; Kornhuber J; Lewczuk P; Jessen F; Wagner M
    J Alzheimers Dis; 2017; 58(3):939-950. PubMed ID: 28527210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.